Cartesian Therapeutics (RNAC) announced positive initial data from its ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic lupus erythematosus, or SLE. The company reported a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback